Peter Attia· MD
Now of course once they find out they're pregnant usually they're usually counled to stop by.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Now of course once they find out they're pregnant usually they're usually counled to stop by.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
So there is a registry and so far to my knowledge there haven't been um reported birth defects and that type of thing but obviously we're talking about small number of patients at this point.
Now, having said that, there have been lots of you may have read about ampic babies like people getting pregnant on GOP1. So there is a registry and so far to my knowledge there haven't been um reported birth defects and that type of thing but obviously we're talking about small number of patient. Yeah that's an interesting point. I I now that you mentioned that I I now recall hearing about that. So so presumably these are women who have taken either you know semiglutide tepatide and presumably they get pregnant either intentionally or not. Right. Um, okay. So, that's a very interesting interesting registry to follow. Right. Right. Now, of course, once they find out they're pregnant, usually they're usually counled to stop by. Yeah. So, we don't know what would happen if you continue. I don't think anybody wants to do that study at the moment.
If a woman's taking a GLP1 receptor agonist is the difference between between her having gestational diabetes and not maybe it's considered. Of course, we would typically turn to something like metformin as a firstline therapy there where we have much more ongoing safety data.